GIMAP7

Across TCGA pan-cancer cohorts, GIMAP7 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GIMAP7 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GIMAP7 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GIMAP7 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where GIMAP7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.980	0.621	<.001	62	view →
CCRCC	OS	Quartile	All	0.923	0.702	.007	23	view →
LUAD	DFS	Quartile	All	0.889	0.503	<.001	13	view →
HNSC	DFS	Median	II,III,IV	0.696	0.877	.013	11	view →
COAD	DFS	Quartile	III,IV	0.837	1.000	.044	6	view →
LSCC	DFS	Median	II,III,IV	0.568	0.815	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GIMAP7–PDAC (DFS)

Open the PDAC breakdown →